Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Harvard Bioscience, Inc. (HBIO) had Cost of Goods Sold of $9.56M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$23.73M |
|
$-2.85M |
|
|
Cost of Goods Sold |
$9.56M |
$14.17M |
|
$22.02M |
|
$1.71M |
|
$-4.91M |
|
$-3.20M |
|
$-3.20M |
|
$-2.85M |
|
$-2.85M |
|
$-2.85M |
|
$-2.85M |
|
$1.71M |
|
$3.68M |
|
4.44M |
|
4.44M |
|
$-0.60 |
|
$-0.60 |
|
| Balance Sheet Financials | |
$48.23M |
|
$4.79M |
|
$31.85M |
|
$80.07M |
|
$21.96M |
|
$35.87M |
|
$44.38M |
|
$66.34M |
|
$13.73M |
|
$-3.46M |
|
$13.73M |
|
4.47M |
|
| Cash Flow Statement Financials | |
$6.73M |
|
$-1.86M |
|
$-1.29M |
|
$4.11M |
|
$8.61M |
|
$4.51M |
|
$1.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.20 |
|
-- |
|
-- |
|
0.72 |
|
2.61 |
|
59.71% |
|
7.20% |
|
7.20% |
|
-- |
|
-13.50% |
|
-11.99% |
|
$5.47M |
|
-- |
|
-- |
|
-- |
|
0.30 |
|
0.46 |
|
1.48 |
|
60.83 |
|
-20.73% |
|
82.19% |
|
-3.56% |
|
-5.74% |
|
$3.07 |
|
$1.23 |
|
$1.52 |
|